PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock, offered at a price of $18.95 per share. The offering is expected to close on or about February 24, 2014, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock. Jefferies LLC, Barclays Capital Inc. and Deutsche Bank Securities are acting as joint book-runners for the offering. Piper Jaffray & Co. is acting as lead manager for the offering and Trout Capital acted as a financial advisor to the Company.
Help employers find you! Check out all the jobs and post your resume.
